Lactoferrin is an iron-binding glycoprotein present in milk, tears, saliva, vaginal secretions, semen, bronchoalveolar lavage fluid, and specific granules of polymorphonuclear leukocytes (PMNs) (10, 13, 39) . Biological properties ascribed to this protein include the regulation of absorption of iron and other metals in the gastrointestinal tract, modulation of both the production of PMNs and the growth of animal cells, and finally antimicrobial activity against bacteria and yeasts (34, 40, 45) . Initially, the antimicrobial effect of lactoferrin was considered to be a function of its ability to chelate iron, with the protein inhibiting microbial growth through nutritional deprivation of iron (21) . However, several investigators have suggested that lactoferrin has other effects against microorganisms. Work by Arnold and associates (2, 3, 7, 8, 30) has suggested that lactoferrin is capable of a direct bacterial effect on strains of Streptococcus mutans, Vibrio cholerae, Escherichia coli, Actinobacillus actinomycetemcomitans, and Legionella pneumophila. Additionally, several research groups have found that the antimicrobial activity of lactoferrin against E. coli strains is enhanced by concurrent exposure of the bacteria to immunoglobulin G or secretory immunoglobulin A (44, 48, 49) . More recently, we have found that human lactoferrin can directly damage the outer membrane of gram-negative bacteria (16) (17) (18) (19) . Lactoferrin causes the release of lipopolysaccharide (LPS) molecules from the membrane and enhances bacterial susceptibility to hydrophobic antibiotics and human lysozyme. These effects on the outer membrane of gram-negative bacteria appear to be related to a direct interaction of lactoferrin with the bacterial cell (16) .
Work with bovine lactoferrin has found that the antimicrobial activity of an enzymatic hydrolysate generated by digestion with porcine pepsin is stronger than that of the whole protein against an E. coli 0111 isolate (51) . The bacteriostatic activity is associated with low-molecularweight peptide fragments, and an active lactoferrin peptide fragment has been purified by reverse-phase high performance liquid chromatography (5) . Sequence analysis indicates that this peptide fragment is 25 amino acids long (Phe-Lys-Cys-Arg-Arg-Trp-Gln-Trp-Arg-Met-Lys-Lys-LeuGly-Ala-Pro-Ser-Ile-Thr-Cys-Val-Arg-Arg-Ala-Phe) and has exact homology with an amino-terminal segment of the whole lactoferrin sequence, as reported by Pierce et al. (43) and by Goodman and Schanbacher (26) . The segment of the N terminus involved is distinctly separate from the two iron-binding regions of the protein. It contains five arginine and three lysine residues, making it strongly cationic, and lacks detectable carbohydrate. A search of the NBRF-PIR databank found that it has strong homology with an N-terminal region of mouse lactoferrin, but not with other cationic antimicrobial proteins. In this report, we have investigated the effects of both whole bovine lactoferrin and its peptide fragment, lactoferricin, on the gram-negative bacterial outer membrane and have further characterized the antimicrobial activity of lactoferricin.
MATERIALS AND METHODS
Lactoferrin and lactoferricin. Bovine milk lactoferrin was prepared from fresh skim milk by the method described by Law (16, 18) . Briefly, the LPS of each of these bacteria was intrinsically radiolabeled through the incorporation of tritiated galactose into the carbohydrate component of the LPS molecule (6, 17, 18, 25, 28, 29, 56) . The strain to be tested was grown at 37°C in 1 ml of defined medium (WMS broth, Davis minimal medium, Luria broth, or Luria broth with calcium [16, 18] RESULTS LPS release studies. To study the effects of bovine lactoferrin and lactoferricin on the outer membrane, we determined whether they could release LPS from three bacterial strains, E. coli CL99 1-2, S. typhimurium SL696, and S. montevideo SL5222. In initial studies performed with bacterial cells grown with 2 mM calcium, we found that 18 ,uM lactoferricin caused a dramatic release of 3H-labeled LPS from all three bacterial strains (Table 1 ). In comparison, the approximately the same molar concentration of whole bovine lactoferrin protein caused a lower degree of LPS release from the two Salmonella strains. These results are comparable to those from a previous study with human lactoferrin (18) and suggest that both bovine lactoferrin and lactoferricin, the peptide with N-terminal region, can damage the gram-negative bacterial outer membrane.
Prior work has indicated that growing bacterial cells in the presence of increasing concentrations of calcium ions increased the percentage of LPS that could be released by EDTA and human lactoferrin (16) . Presumably, when the outer membrane is assembled in the presence of high concentrations of cations, increased numbers of cations are incorporated into the membrane to stabilize the anionic charge of the LPS core. The increased amount of cations within the membrane may then make the membrane more susceptible to factors that alter the cation-LPS relationship. Using this hypothesis, we similarly studied the effect of calcium in growth medium on the ability of bovine lactoferrin and lactoferricin to release LPS from S. typhimurium SL696 ( Table 1) . As previously noted with human lactoferrin, the amount of LPS released from the bacterial membrane by bovine lactoferrin significantly increased as the 4.6 ± 1.0 (7) 22.8 ± 6.8d (5) 45.5 ± 1.8e (7) Luria broth + 10 mM calcium 4.9 ± 1.1 (5) 58.0 ± 6.7fg (5) 47.4 + O.7f (5) a Significantly different from value obtained with HBSS-CM and bovine lactoferrin (P < 0.05).
b Significantly different from value obtained with HBSS-CM alone (P < 0.05).
c Significantly different from value obtained with HBSS-CM and bovine lactoferrin (P < 0.0001).
d Significantly different from value obtained with HBSS-CM (P < 0.005). e Significantly different from value obtained with HBSS-CM and bovine lactoferrin (P < 0.05).
f Significantly different from value obtained with HBSS-CM (P < 0.0001). g Significantly different from value obtained with Luria broth and no supplemental calcium (P < 0.01).
concentration of calcium ions in the growth medium increased. In contrast, the ability of lactoferricin to release LPS appeared to be independent of the calcium concentration of the growth medium.
With the high degree of radiolabel being released, concurrent experiments were performed to test the effect of bovine lactoferrin and lactoferricin on bacterial viability under these experimental conditions. Although lactoferrin had no effect, lactoferricin caused a greater than 99% decrease in bacterial CFU in HBSS-CM during the 30-min incubation for each of the Salmonella strains.
Bacterial susceptibility to human lysozyme. To determine whether the ability of bovine lactoferrin and lactoferricin to release LPS from the bacterial cell also altered the permeability of the outer membrane, we studied the effects of the proteins on bacterial susceptibility to human lysozyme. As previously observed with human lactoferrin, we found that there was increased killing of E. coli CL99 1-2 in 1% Bacto Peptone medium containing bovine lactoferrin and human lysozyme (Fig. 1) . Similarly, there was also increased killing of bacterial cells that were concurrently exposed to lactoferricin and lysozyme as opposed to either of these compounds alone (Fig. 2) . This interaction was dependent on the concentration of lactoferricin, with increasing bacterial killing seen as lactoferricin concentration was increased from 2 to 8 ,ug/ml (data not shown).
LPS binding studies. Human lactoferrin and polycationic agents not only alter bacterial outer membrane permeability but also directly bind LPS (16, 38) . We attempted to ascertain whether bovine lactoferrin and lactoferricin also have this property. In studies with intrinsically radiolabeled LPS, we found that bovine lactoferrin and lactoferricin have similar abilities to bind LPS, and each has a stronger ability to bind LPS than do BSA and poly-L-lysine (Fig. 3 ). An exact calculation of the number of LPS binding sites and the Kd for the interactions with lactoferrin or lactoferricin is not possible both because of the inability to define the molar concentration of LPS (because of size variability) and because of the capacity for free LPS molecules to aggregate in solution.
Bactericidal activity of lactoferricin. As the experiments above indicated that lactoferricin has bactericidal activity in addition to an effect on the gram-negative bacterial outer membrane, further time-kill studies were performed. In experiments with E. coli CL99 1-2 in 1% Bacto Peptone medium, we found that lactoferricin exhibited a consistent bactericidal effect (Fig. 4) . The activity was proportional to the concentration of lactoferricin and inversely proportional to the bacterial inoculum. Specifically, lactoferricin at a concentration of 100 ,ug/ml was highly bactericidal, regardless of the inoculum size. Over a 1-h incubation, there was a greater than 99% reduction in CFU, and subsequent bacterial killing continued through 24-h incubation. A lactoferricin concentration of 10 ,ug/ml was also bactericidal, but the activity of this lower lactoferricin concentration was inoculum dependent. The lactoferricin concentration of 1.0 ,ug/ml had no apparent effect on the bacterial cells.
As these studies had been performed with stationaryphase organisms, time-kill curves were also performed with lactoferricin against log-phase bacteria for which a greater bactericidal effect was observed (data not shown). Additionally, because prior work found that a bactericidal effect of lactoferrin against L. pneumophila was seen against broth- (Fig. 5) . A rapid bactericidal effect for lactoferricin was again observed. These results suggest that the observed variation in activity with inoculum size is not due to the rapid emergence of resistant organisms but instead relates to the ratio of lactoferricin molecules to bacterial cells.
Our prior work with human lactoferrin indicated that lactoferrin and lysozyme could kill gram-negative organisms only under low osmotic conditions (16) . To evaluate whether the in vitro killing by lactoferricin was similarly related to the osmolarity of the medium, we tested the activity of the peptide in Bacto Peptone medium supplemented with myoinositol, a sugar not metabolized by E. coli CL99 1-2. We found that increasing the osmolarity of the medium up to 288 mosM had no impact on the bactericidal effect (Fig. 6 ).
The segment of the bovine lactoferrin N-terminus-containing lactoferricin is distinct from the two iron-binding regions of the protein, which suggests that iron would not influence its activity. In testing this hypothesis, we found that 80 ,uM ferric chloride had no effect on the activity of 18 ,uM lactoferricin, although it did inhibit the effect of 2 ,uM lactoferricin, particularly after incubation for 24 h (Fig. 7) . In contrast, 80 uLM ferric chloride completely inhibited the activity of 20 ,uM bovine lactoferrin. The fact that the inhibition of lactoferricin occurred at a higher iron-to-protein ratio than the inhibition of lactoferrin suggests that the effect of ferric iron on the activity of lactoferricin is due to a different mechanism than that for bovine lactoferrin.
Similarly, it has been noted that calcium and magnesium can affect the antimicrobial activities of human lactoferrin and several neutrophil-derived cationic proteins, including the bactericidal/permeability-increasing protein (BPI), the defensins, and the bactenecins (18, 35, 47, 52 ). Thus, we tested the effects of increasing calcium and magnesium levels on the antimicrobial activity of lactoferricin (Fig. 8) . We found that both cations could inhibit the activity of lactoferricin against E. coli CL99 1-2, but the peptide retained a demonstrable effect at calcium and magnesium concentrations of 100 ,M.
MIC and MBC studies. To further evaluate the spectrum of antimicrobial activity of lactoferricin, we determined the MICs and MBCs of the peptide against a variety of microorganisms in 1% Bacto Peptone medium (Table 2 ). With 10 Gram-negative strains, the MICs ranged from 1.6 to 5.2 ,ug/ml. For isolates of the family Enterobacteriaceae, the MBCs were almost identical to the MICs. In contrast, for two Pseudomonas aeruginosa isolates, the peptide had only an inhibitory effect, with the MBC greater than 125 p,g/ml.
For three gram-positive strains and two Candida albicans isolates, the MICs and MBCs of lactoferricin were very close and ranged from 0.8 to 13.2 ,ug/ml. TEM studies. To further characterize the bactericidal effect of lactoferricin, we used TEM to examine E. coli CL99 1-2 cells treated with lactoferricin (Fig. 9) . We found that bacterial cells exposed to 100 ,ug of lactoferricin per ml immediately showed an altered cell membrane morphology, with the appearance of membrane "blisters. elements, in addition to membrane blistering. These effects are distinctly different from those noted with whole human lactoferrin which has no effect on bacterial morphology by TEM (16) . DISCUSSION In this work, we have found that bovine lactoferrin alters the structure of the gram-negative bacterial outer membrane. The protein causes both the release of structural LPS molecules and an increase in killing of bacteria by human lysozyme. In this fashion, it appears to have an effect similar to that of human lactoferrin (16) (17) (18) (19) . Experiments with human lactoferrin had indicated that its membrane activity was related to an ability to directly interact with the membrane and that the protein binds LPS molecules (16) . We have now found that the bovine protein shares this latter property. . 7 . Evaluation of the bactericidal activity of bovine lactoferrin and lactoferricin toward E. coli CL99 1-2 in 1% Bacto Peptone alone or supplemented with ferric chloride. Lactoferrin and lactoferricin were incubated in medium with iron for 1 h at 37°C prior to the addition of bacteria. Each value shown is the mean ± standard error of the mean from two or three experiments. Symbols-0, no supplement; El, 2 mg of bovine lactoferrin per ml; >, 10 ,ug of lactoferricin per ml; O, 100 ,ug of lactoferricin per ml; 0, 80 p,M Fe3"; E, 2 mg of bovine lactoferrin per ml and 80 ,uM Fe3+; *, 10 pg of lactoferricin per ml and 80 p,M Fe3+; *, 100 ,ug of lactoferricin per ml and 80 p,M Fe3+
The concentration of lactoferrin required to alter the outer membrane is high, indicating that this activity will not occur in all physiologic environments. However, lactoferrin has been found at the following levels in body fluids: 0.5 ± 0. mg/ml (mean ± standard deviation) in pooled pulmonary secretions; above 6 mg/ml in preterm colostrum; and above 14 mg/ml in infected parotid fluid (9, 41, 50) . Additionally, lactoferrin is released from PMNs in response to cytokine stimulation and in response to gram-negative bacterial infection. As the levels of lactoferrin in plasma during acute sepsis can reach 0.2 mg/ml, it is likely that local concentrations at sites of inflammation will be in the range of milligrams per milliliter (27, 31) . Thus, lactoferrin levels similar to those studied may be found in sites of bacterial infection, as well as within the neutrophil phagolysosome and within colostral milk.
In addition to this activity of whole bovine lactoferrin, we have found that the peptide fragment of the protein, lactoferricin, has very comparable effects on the outer membrane. These observations suggest that at a minimum the amino-terminal domain of the whole protein comprising lactoferricin makes a major contribution to the outer membrane activity of lactoferrin. It is conceivable that this domain is the sole site in lactoferrin contributing to the membrane effects. This hypothesis is consistent with recent X-ray crystallographic observations with human lactoferrin (1) . Crystallographic analysis indicates that the region of human lactoferrin approximating the lactoferricin segment of bovine lactoferrin is surface exposed, and thus in a location where it could interact with either free LPS or a bacterial cell.
However, in addition to its outer membrane effects, lact- (22, 24, 33, 37, 47, 53, 54) . Although the amino acid sequence of lactoferricin is unique, like these other proteins, it is highly cationic and alters outer membrane permeability (33, 47, 53, 54) . With BPI, it shares an ability to bind LPS (38) , and with the defensins, it shares an ability to kill gram-negative bacteria and C. albicans (22, 35) . Additionally, both BPI and the defensins produce alterations in the gram-negative bacterial outer membrane morphology observable by TEM, although neither produce the blister-like effects of lactoferricin (33, 52) .
It is important to consider that lactoferricin is released from whole bovine lactoferrin after hydrolysis with pepsin (5), which raises the possibility that the peptide fragment is released from orally ingested lactoferrin in vivo. Moreover, in that an aspartic protease of Penicillium duponti also appears to release the peptide from lactoferrin (51) , it is possible that lactoferricin will also be freed from lactoferrin in vivo under other conditions when the whole protein is exposed to proteases. One important environment in which this could occur is the phagolysosome of PMNs and macrophages, where a variety of proteases is present (20) . Al (14, 15 Similarly, when lactoferrin becomes iron saturated, there are changes in both the three-dimensional structure of the molecule and its molecular flexibility (4). Thus, while the aminoterminal domain of lactoferrin is not associated with the chelating activity of the molecule, the decrease in overall molecular flexibility associated with iron chelation may decrease the ability of the protein to interact with the bacterial cell. It is also possible that ferric iron could interfere with the activity of lactoferrin and lactoferricin in a manner similar to the divalent cations. Such an effect is particularly likely in relation to the effect of iron on lactoferricin, which is distinct from the iron-binding domain of whole lactoferrin and should therefore not be influenced by conformational changes related to chelation. Each of these hypotheses will need experimental confirmation.
